MSH2 and colorectal carcinoma: Although not specifically tested in LS-CRC, FSP-based vaccination induced significant humoral and T-cell responses in a first-in-human, phase I/IIa clinical trial (113) as well as in a mouse model of conditional MSH2 knockout (114).